Royalty Pharma offers to buy Elan for about $6.5B NEW YORK (AP) — Royalty Pharma says that it wants to buy Elan Corp. PLC for about $6.5 billion, but has yet to receive a response from the Irish drug maker. The $11 per share offer, which was made earlier this month and applies to both Elan's regular and American depository shares, represents a 4 percent premium over its Friday closing ADS price.